menu
    • menu

    Company profile for Altimmune

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Altimmune is a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies. Our diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic Hepatitis B (HepTcell), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX™ and NasoShield™).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AltimmuneUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    910 Clopper Road Suite 201S, Gaithersburg, MD 20878
    Telephone
    Telephone
    (240) 654-1450
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://altimmune.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/vaxin-inc-
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/hashtag/altimmune?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Altimmune Announces CEO Transition And Succession Plan
    Altimmune Announces CEO Transition And Succession Plan

    01 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/01/3196904/0/en/Altimmune-Announces-CEO-Transition-and-Succession-Plan.html

    GLOBENEWSWIRE
    01 Dec 2025
    Share Share
    Altimmune To Join Piper Sandler Healthcare Conference
    Altimmune To Join Piper Sandler Healthcare Conference

    26 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/26/3195052/0/en/Altimmune-to-Participate-in-the-Piper-Sandler-37th-Annual-Healthcare-Conference.html

    GLOBENEWSWIRE
    26 Nov 2025
    Share Share
    Altimmune Poised For $1B+ Opportunity As MASH Drug Aces Phase IIb
    Altimmune Poised For $1B+ Opportunity As MASH Drug Aces Phase IIb

    13 Nov 2025

    // BIOSPACE

    https://www.biospace.com/drug-development/altimmune-poised-for-1b-opportunity-as-mash-drug-aces-phase-iib

    BIOSPACE
    13 Nov 2025
    Share Share
    Altimmune Announces Publication of IMPACT Phase 2b Trial Data
    Altimmune Announces Publication of IMPACT Phase 2b Trial Data

    11 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/11/3185445/0/en/Altimmune-Announces-Publication-of-IMPACT-Phase-2b-Trial-Data-in-The-Lancet-and-Concurrent-Late-Breaking-Oral-Presentation-at-AASLD-The-Liver-Meeting-2025.html

    GLOBENEWSWIRE
    11 Nov 2025
    Share Share
    Altimmune Show AI-Based Liver Fibrosis Data From Pemvidutide Ph2b
    Altimmune Show AI-Based Liver Fibrosis Data From Pemvidutide Ph2b

    07 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/07/3183618/0/en/Altimmune-Presents-AI-Based-Analysis-of-Liver-Fibrosis-Reduction-from-IMPACT-Phase-2b-Trial-of-Pemvidutide-in-MASH-in-Late-breaking-Poster-at-AASLD-The-Liver-Meeting-2025.html

    GLOBENEWSWIRE
    07 Nov 2025
    Share Share
    Altimmune To Participate In Two Upcoming Investor Conferences
    Altimmune To Participate In Two Upcoming Investor Conferences

    05 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/05/3181348/0/en/Altimmune-to-Participate-in-Two-Upcoming-Investor-Conferences.html

    GLOBENEWSWIRE
    05 Nov 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search